Synaptic vesicle protein 2 (SV2) is required for normal calcium-regulated secretion of hormones and neurotransmitters. Neurons lacking the two most widely expressed isoforms, SV2A and SV2B, have a reduced readily releasable pool of synaptic vesicles, indicating that SV2 contributes to vesicle priming. The presence of putative ATP-binding sites in SV2 suggested that SV2 might be an ATP-binding protein. To explore this, we examined the binding of the photoaffinity reagent 8-azido-ATP[␥] biotin to purified, recombinant SV2 in the presence and absence of other nucleotides. Our results indicate that SV2A and SV2B bind nucleotides, with the highest affinity for adenine-containing nucleotides. SV2A contains two binding sites located in the cytoplasmic domains preceding the first and seventh transmembrane domains. These results suggest that SV2-mediated vesicle priming could be regulated by adenine nucleotides, which might provide a link between cellular energy levels and regulated secretion.Calcium-regulated secretion is an adaptation of generic soluble NSF attachment protein receptor (SNARE)-mediated 2 membrane trafficking. Its unique properties depend on specialized proteins that control the rate at which vesicles become competent for fusion. One of these proteins, SV2 (1), is specifically expressed in neurons and endocrine cells, where it is localized to vesicles that undergo regulated secretion. Mammalian genomes contain three isoforms of SV2 (2-5), termed SV2A, SV2B, and SV2C. Of these, SV2A is the most widely expressed (6) and is the isoform whose expression is required for survival (7,8). SV2A is also the binding site of the anti-epileptic drug levetiracetam (9) and thus the only known synaptic vesicle target of a central nervous system-directed therapy.When SV2 expression is knocked out or reduced in neurons, chromaffin cells, or pancreatic islet cells, regulated secretion is decreased because of a reduction in the number of vesicles primed for release (10 -12). Synapses from SV2 knock-out mice have equal numbers of vesicles attached to the plasma membrane (10) and fewer SNARE complexes (12). This suggests that SV2 acts after vesicle docking and before SNARE complex assembly, which occurs just prior to fusion. How SV2 contributes to vesicle priming remains unknown. All SV2 proteins are predicted to have 12 transmembrane domains, and all contain the signature motifs of major facilitator transporters (13,14). Loss of SV2 does not affect vesicular uptake of calcium (11) 3 or neurotransmitters.4 It is therefore unclear whether SV2 acts as a transporter or, like adenylate cyclase, has a transporter-like structure but performs a nontransport function (15).Several major facilitator transporters contain nucleotidebinding sites and in some cases ATP binding regulates transporter activity. For example, ATP inhibits glucose transport by the human erythrocyte glucose transporter (16 -18). SV2A contains two weak Walker ATP-binding domains (19) located in the cytoplasmic N terminus (a.a. 129 -143) and a region that spans the...